Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.
You may also be interested in...
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint
CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.